drugset / Trial / NCT01283373
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I, multicenter, open-label, dose-escalation study of DSTP3086S administered as a single agent by intravenous (IV) infusion to patients with metastatic Castration-Resistant Prostate Cancer (CRPC).
Timeline
- Start
- 2011-03
- Primary completion
- 2016-01
- Completion
- 2016-01
Publications
- Martiniova L, Zielinski RJ, Lin M, DePalatis L, Ravizzini GC. The Role of Radiolabeled Monoclonal Antibodies in Cancer Imaging and ADC Treatment. Cancer J. 2022 Nov-Dec 01;28(6):446-453. doi: 10.1097/PPO.0000000000000625.
- Danila DC, Szmulewitz RZ, Vaishampayan U, Higano CS, Baron AD, Gilbert HN, Brunstein F, Milojic-Blair M, Wang B, Kabbarah O, Mamounas M, Fine BM, Maslyar DJ, Ungewickell A, Scher HI. Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019 Dec 20;37(36):3518-3527. doi: 10.1200/JCO.19.00646. Epub 2019 Nov 5.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DSTP3086S | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | DSTP3086S | Monoclonal antibody | 0.8 mg/kg | Intravenous |
| Subject | DSTP3086S | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | DSTP3086S | Monoclonal antibody | 2.25 mg/kg | Intravenous |
| Subject | DSTP3086S | Monoclonal antibody | 2.4 mg/kg | Intravenous |
| Subject | DSTP3086S | Monoclonal antibody | 2.8 mg/kg | Intravenous |